C Sessa

Summary

Affiliation: Oncology Institute of Southern Switzerland
Country: Switzerland

Publications

  1. doi request reprint Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors
    Cristiana Sessa
    Istituto Oncologico della Svizzera IOSI, Ospedale San Giovanni, 6500, Bellinzona, Switzerland
    Invest New Drugs 31:1236-43. 2013
  2. pmc T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein
    Julien Laurent
    Division of Experimental Oncology, Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Transl Med 11:5. 2013
  3. doi request reprint Update on PARP1 inhibitors in ovarian cancer
    C Sessa
    Oncology Institute of Southern Switzerland, San Giovanni Hospital, Bellinzona, Switzerland
    Ann Oncol 22:viii72-viii76. 2011
  4. ncbi request reprint Randomized single-agents trials in recurrent epithelial ovarian cancer
    C Sessa
    Istituto Oncologico della Svizzera Italiana IOSI, Bellinzona, Switzerland
    Int J Gynecol Cancer 15:247-51. 2005
  5. doi request reprint Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours
    C Sessa
    Istituto Oncologico della Svizzera Italiana, Via Ospedale, 6500 Bellinzona, Switzerland Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
    Eur J Cancer 45:2116-22. 2009
  6. doi request reprint Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer
    C Sessa
    Istituto Oncologico della Svizzera Italiana IOSI, Ospedale San Giovanni, Via Ospedale, 6500 Bellinzona, Switzerland
    Eur J Cancer 45:1153-61. 2009
  7. ncbi request reprint Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer
    O Pagani
    Istituto Oncologico della Svizzera Italiana, Ospedale S Giovanni, Bellinzona, Switzerland
    Ann Oncol 10:539-45. 1999
  8. ncbi request reprint Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study
    O Pagani
    Istituto Oncologico della Svizzera Italiana, Ospedale S Giovanni, Bellinzona, Switzerland
    Ann Oncol 11:985-91. 2000
  9. ncbi request reprint Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243)
    C Sessa
    Istituto Oncologico della Svizzera Italiana, Division of Oncology, Ospedale San Giovanni, 6500 Bellinzona, Switzerland
    Cancer Chemother Pharmacol 44:403-10. 1999
  10. doi request reprint Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel
    C Sessa
    Department of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
    Ann Oncol 21:1315-22. 2010

Detail Information

Publications40

  1. doi request reprint Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors
    Cristiana Sessa
    Istituto Oncologico della Svizzera IOSI, Ospedale San Giovanni, 6500, Bellinzona, Switzerland
    Invest New Drugs 31:1236-43. 2013
    ....
  2. pmc T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein
    Julien Laurent
    Division of Experimental Oncology, Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Transl Med 11:5. 2013
    ....
  3. doi request reprint Update on PARP1 inhibitors in ovarian cancer
    C Sessa
    Oncology Institute of Southern Switzerland, San Giovanni Hospital, Bellinzona, Switzerland
    Ann Oncol 22:viii72-viii76. 2011
    ....
  4. ncbi request reprint Randomized single-agents trials in recurrent epithelial ovarian cancer
    C Sessa
    Istituto Oncologico della Svizzera Italiana IOSI, Bellinzona, Switzerland
    Int J Gynecol Cancer 15:247-51. 2005
    ..These data confirm the role of pegylated liposomal doxorubicin in the management of REOC and indicate that the identification of new active drugs in this disease is relevant but also feasible only in platinum-sensitive patients...
  5. doi request reprint Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours
    C Sessa
    Istituto Oncologico della Svizzera Italiana, Via Ospedale, 6500 Bellinzona, Switzerland Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
    Eur J Cancer 45:2116-22. 2009
    ..Plasma pharmacokinetics at cycle 1 and a preliminary anti-tumour activity assessment in ovarian and non-small cell lung cancer (OC, NSCLC) were secondary objectives...
  6. doi request reprint Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer
    C Sessa
    Istituto Oncologico della Svizzera Italiana IOSI, Ospedale San Giovanni, Via Ospedale, 6500 Bellinzona, Switzerland
    Eur J Cancer 45:1153-61. 2009
    ..No pharmacokinetic interaction between T and D was observed. The lack of cumulative toxicity and related complications and the promising activity in STS support further development of T+D...
  7. ncbi request reprint Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer
    O Pagani
    Istituto Oncologico della Svizzera Italiana, Ospedale S Giovanni, Bellinzona, Switzerland
    Ann Oncol 10:539-45. 1999
    ....
  8. ncbi request reprint Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study
    O Pagani
    Istituto Oncologico della Svizzera Italiana, Ospedale S Giovanni, Bellinzona, Switzerland
    Ann Oncol 11:985-91. 2000
    ..We report here the overall results of the combination of epidoxorubicin (E) 90 mg/m2 and docetaxel (D) 75 mg/m2 as first-line chemotherapy in ABC...
  9. ncbi request reprint Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243)
    C Sessa
    Istituto Oncologico della Svizzera Italiana, Division of Oncology, Ospedale San Giovanni, 6500 Bellinzona, Switzerland
    Cancer Chemother Pharmacol 44:403-10. 1999
    ....
  10. doi request reprint Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel
    C Sessa
    Department of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
    Ann Oncol 21:1315-22. 2010
    ..Pharmacodynamic studies in plasma, peripheral blood mononuclear cells (PBMCs) and skin biopsies and pharmacokinetic (PK) interaction studies at cycles 1 and 2 were carried out...
  11. ncbi request reprint Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule
    C Sessa
    IOSI, Bellinzona, Switzerland
    Ann Oncol 18:1548-53. 2007
    ..The improved solubility of BMS-310705 allowed a cremophore-free formulation that avoided the need for pre-medication...
  12. ncbi request reprint Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin
    C Sessa
    Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland
    Eur J Cancer 40:563-70. 2004
    ..The higher than expected myelotoxicity of the 3-weekly schedule is unexplained by the investigated interactions. Lack of enhanced doxorubicinol formation in human myocardium is consistent with the cardiac safety of the regimen...
  13. ncbi request reprint Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer
    T De Pas
    Division of Medical Oncology, European Institute of Oncology, Milano, Italy
    Ann Oncol 11:821-7. 2000
    ..We performed a phase I study to determine the maximum-tolerated dose (MTD), antitumor activity and pharmacokinetics of GEM and TAX given weekly in chemo-naïve patients with advanced NSCLC...
  14. ncbi request reprint Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer
    O Pagani
    Institute of Oncology of Southern Switzerland IOSI, Ospedale S Giovanni, Bellinzona, Switzerland
    Ann Oncol 16:1609-17. 2005
    ....
  15. doi request reprint Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours
    A Perotti
    Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
    Ann Oncol 20:741-5. 2009
    ..N-cadherin is expressed also on tumour cells and the anti-N-cadherin cyclic pentapeptide ADH-1, tested in the present study, can exert a direct antitumour effect...
  16. ncbi request reprint In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743)
    M Ghielmini
    Division of Oncology, Ospedale S Giovanni, Bellinzona, Switzerland
    Ann Oncol 9:989-93. 1998
    ..The present study was undertaken to compare the toxicity of different schedules of ET-743 against human hemopoietic progenitors and tumour cell lines...
  17. ncbi request reprint Docetaxel and epirubicin in advanced breast cancer
    C Sessa
    Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland
    Oncologist 6:13-6. 2001
    ..These data and those of comparable series suggest that the combination of epirubicin and docetaxel is tolerable and active, and that it should be further developed clinically...
  18. ncbi request reprint Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors
    C Sessa
    Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland
    Ann Oncol 18:561-8. 2007
    ..A phase I design of concerted dose escalation and dosing duration was implemented to assess the potential schedule dependency of tolerability that emerged from animal studies...
  19. ncbi request reprint Phase I-II study of escalating doses of amifostine combined with high-dose cyclophosphamide
    M Ghielmini
    Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona
    Cancer Chemother Pharmacol 47:532-6. 2001
    ..To evaluate the feasibility and clinical effects of increasing doses of amifostine administered four times in 1 day with high-dose (HD) cyclophosphamide (CTX)...
  20. pmc Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer
    M Ghielmini
    Servizio Oncologico Cantonale, Ospedale San Giovanni, Bellinzona, Switzerland
    Br J Cancer 80:1058-61. 1999
    ..We concluded that, in patients with lung cancer, melatonin given orally at a dose of 40 mg per day for 21 days in the evening, does not protect against the myelotoxic effect of carboplatin and etoposide...
  21. ncbi request reprint Oxaliplatin in ovarian cancer
    C Sessa
    Division of Oncology, Ospedale San Giovanni, Bellinzona, Switzerland
    Ann Oncol 10:55-7. 1999
    ..Further clinical development of L-OHP needs to take into account the characteristics of other available active drugs and the distinctive preclinical and clinical features of this DACH platinum complex...
  22. ncbi request reprint Phase II study of intravenous menogaril in patients with advanced breast cancer
    C Sessa
    Division of Oncology, Ospedale San Giovanni, Switzerland
    J Natl Cancer Inst 80:1066-9. 1988
    ..Phlebitis and erythema along the vein injected occurred in 34% and 17% of the cases, respectively. Menogaril is an active drug used in the treatment of patients with advanced breast cancer who have not had prior systemic therapy...
  23. ncbi request reprint Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule
    C Sessa
    Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland
    Eur J Cancer 38:2388-96. 2002
    ....
  24. doi request reprint Adjuvant therapy for colon cancer: present and perspectives
    S De Dosso
    Medical Oncology, Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland
    Cancer Treat Rev 35:160-6. 2009
    ..The inclusion of molecular targeted agents in combination regimens with cytotoxics, already proven effective in advanced disease, is the main field of development in the most recent protocols of adjuvant therapy...
  25. ncbi request reprint Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors
    C Sessa
    Oncology Institute of Southern Switzerland, Ospedale San Giovanni, 6500 Bellinzona, Switzerland
    Ann Oncol 13:1140-50. 2002
    ..To define the maximum tolerated dose (MTD), the recommended phase II dose, the optimal infusion duration and pharmacokinetics of the semisynthetic taxoid derivative RPR 109881A, given as a 1-h or 3-h infusion every 3 weeks...
  26. ncbi request reprint Classical (HIV-negative) cutaneous Kaposi's sarcoma: a case report and a short review of the literature
    P Sanna
    Istituto Oncologico della Svizzera Italiana, Ospedale San Giovanni, Bellinzona
    Schweiz Med Wochenschr 130:988-92. 2000
    ..Current treatments, in particular radiation therapy, achieve disease control or at least control of disease-related symptoms (mainly pain) in most cases, even when cure is not possible...
  27. pmc Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial
    N Colombo
    Division of Gynecology, University of Milan Bicocca, Milano, Italy
    Br J Cancer 108:1021-6. 2013
    ..This open-label, multicentre, phase 2 trial evaluated the efficacy and tolerability of the mammalian target of rapamycin inhibitor ridaforolimus in women with advanced endometrial cancer...
  28. pmc Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93
    Olivia Pagani
    Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland
    Breast Cancer Res Treat 116:491-500. 2009
    ..03). Chemotherapy significantly improves disease-free survival for postmenopausal women with endocrine-responsive breast cancer, but the magnitude of the effect is substantially attenuated if ER levels are high...
  29. ncbi request reprint Ovarian cancers in pregnancy
    C Sessa
    Ospedale San Giovanni, IOSI, Oncology Institute of Southern Switzerland, Bellinzona
    Recent Results Cancer Res 178:75-8. 2008
  30. ncbi request reprint Patients' estimation of overall treatment burden: why not ask the obvious?
    J Bernhard
    Swiss Institute for Applied Cancer Research, SIAK Coordinating Center, Effingerstrasse 40, 3008 Bern, Switzerland
    J Clin Oncol 20:65-72. 2002
    ..We investigated the clinical validity of patients' estimation of overall treatment burden. This measure was expected to be responsive to the wide spectrum of reactions on treatment and thus less precise for specific effects...
  31. ncbi request reprint Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies
    J H M Schellens
    Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam
    Invest New Drugs 20:83-93. 2002
    ..Prospective implementation of large scale population pharmacokinetic-dynamic analysis is feasible and important to establish whether interpatient variability in drug exposure is a major determinant of toxicity or activity...
  32. ncbi request reprint Enzymuria in carboplatin nephrotoxicity
    E Damiani
    Clinica Medica, , Italia
    Tumori 73:487-91. 1987
    ..A transient increase in plasma creatinine and/or abnormal proteinuria was observed in 6 cases. Impaired renal function prior to therapy seems to be a predisposing factor to the nephrotoxicity...
  33. ncbi request reprint 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial
    A D Roth
    Oncosurgery, Department of Surgery, Hôpital Cantonal Universitaire Geneva University Hospital, 24 Micheli du Crest, CH 12ll Geneva 14, Switzerland
    Ann Oncol 15:759-64. 2004
    ..i.v.) with docetaxel and cisplatin for patients with advanced gastric cancer...
  34. pmc Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer
    G Gruber
    Institut für Radiotherapie, Klinik Hirslanden and Swiss Group for Clinical Cancer Research SAKK, Zurich, Switzerland
    Ann Oncol 19:1393-401. 2008
    ..This study evaluates ECS as a predictor of local, axillary, and supraclavicular recurrence...
  35. ncbi request reprint Predicting the maximum-tolerated dose of PNU-159548 (4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin) in humans using CFU-GM clonogenic assays and prospective validation
    D Moneta
    Pharmacia Corporation, Pharmacology Department, 20014 Nerviano, Milan, Italy
    Eur J Cancer 39:675-83. 2003
    ....
  36. ncbi request reprint Cancer drug development in Europe: a selection of new agents under development at the European Drug Development Network
    D Lacombe
    European Organisation for Research and Treatment of Cancer, Assistant Director New Drug Development Program, avenue E Mounier, 83 b11, 1200 Brussels, Belgium
    Cancer Invest 21:137-47. 2003
    ..In this paper, the most interesting drugs under development in each of the three organisations are being described and discussed...
  37. pmc Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies
    S Leyvraz
    Centre Pluridisciplinaire d Oncologie, University Hospital, CHUV BH06, Rue du Bugnon 46, Lausanne, Switzerland
    Br J Cancer 95:1342-7. 2006
    ..This high-dose regimen is toxic but nonetheless feasible in multicentre settings in non elderly patients with good performance status. A high response rate was obtained. Prolonged survival was mainly a function of salvage therapies...
  38. ncbi request reprint Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas
    S Leyvraz
    Centre Pluridisciplinaire d Oncologie, University Hospital, Lausanne, Switzerland
    Ann Oncol 17:646-51. 2006
    ..We investigated the antitumor activity and toxicity of high-dose ifosfamide and doxorubicin, in the context of a multidisciplinary strategy for the treatment of advanced and metastatic, not pretreated, gynecologic sarcomas...
  39. ncbi request reprint The combination of yondelis and cisplatin is synergistic against human tumor xenografts
    M D'Incalci
    Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milan, Italy
    Eur J Cancer 39:1920-6. 2003
    ..The two drugs can be combined at the MTD of each drug, thus indicating there are no overlapping toxicities. These results provide a rationale for testing the combination of Yondelis and DDP in the clinic...
  40. ncbi request reprint Development of distamycin-related DNA binding anticancer drugs
    S Marchini
    Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea, 62- 20157 Milan, Italy
    Expert Opin Investig Drugs 10:1703-14. 2001
    ..g., et-743)...